/NT-BM ) that received AEBP1 nontransgenic (AEBP1 NT ) BM cells. Our in vivo experimental data strongly suggest that macrophage AEBP1 plays critical regulatory roles in atherogenesis, and it may serve as a potential therapeutic target for the prevention or treatment of atherosclerosis.
INTRODUCTION
Atherosclerosis is a killer disease responsible for >50% of deaths in the developed world (1, 2) . Although some researchers seem to focus on atherosclerosis as either a metabolic/lipid disorder or an inflammatory disorder, there is a general consensus among most investigators that atherosclerosis is a complex disease involving both metabolic and inflammatory dysfunctions. Once fully differentiated in the intima, macrophages express a wide range of scavenger receptors that allow internalization of modified lowdensity lipoprotein (LDL). Lipid accumulation in macrophages leads to the activation of signaling pathways that involve activation of peroxisome proliferator-activated receptor (PPAR)-γ1 and liver X receptor α (LXRα), nuclear receptors that function as transcription factors controlling macro phage cholesterol homeostasis (3) (4) (5) (6) (7) . Ligand-bound activated PPARγ1 and LXRα are syner-Atherogenesis is a long-term process that involves inflammatory response coupled with metabolic dysfunction. Foam cell formation and macrophage inflammatory response are two key events in atherogenesis. Adipocyte enhancer-binding protein 1 (AEBP1) has been shown to impede macrophage cholesterol efflux, promoting foam cell formation, via peroxisome proliferator-activated receptor (PPAR)-γ1 and liver X receptor α (LXRα) downregulation. Moreover, AEBP1 has been shown to promote macrophage inflammatory responsiveness by inducing nuclear factor (NF)-κB activity via IκBα downregulation. Lipopolysaccharide (LPS)-induced suppression of pivotal macrophage cholesterol efflux mediators, leading to foam cell formation, has been shown to be mediated by AEBP1. Herein, we showed that AEBP1-transgenic mice (AEBP1 TG ) with macrophage-specific AEBP1 overexpression exhibit hyperlipidemia and develop atherosclerotic lesions in their proximal aortas. Consistently, ablation of AEBP1 results in significant attenuation of atherosclerosis (males: 3. /TG-BM chimeric mice express reduced levels of PPARγ1, LXRα, ATP-binding cassette A1 (ABCA1) and ATP-binding cassette G1 (ABCG1) and increased levels of the inflammatory mediators interleukin (IL)-6 and tumor necrosis factor (TNF)-α compared with macrophages of control chimeric mice (ApoE -/-gistically implicated in the transactivation of several genes for which products are critically involved in mediating macrophage cholesterol efflux and initiating reverse cholesterol transport. Genetic defects or pharmacological inhibition of any component of the macrophage cholesterol efflux pathway leads to an imbalance in cholesterol homeostasis. This result eventually leads to massive accumulation of lipids in the cytoplasmic compartment of macrophages, which acquire a foamy appearance and transform into lipid-engorged foam cells, a hallmark of fatty streak and atherosclerotic lesion formation. Because atherosclerosis is a multigenic disease, understanding the roles and expression patterns of genes with known and unknown functions is critical in understanding the molecular mechanisms underlying atherogenesis.
Adipocyte enhancer-binding protein 1 (AEBP1) is a ubiquitously expressed transcriptional repressor for which expression is highest in white and brown adipose tissues, liver, lung, spleen and brain (8) . Recently, AEBP1 was shown to be abundantly expressed in primary macro phages and macrophage cell lines (9) (10) (11) . We demonstrated that AEBP1 represses the expression of PPARγ1 and LXRα in a dose-dependent, DNA binding-dependent fashion, which is accompanied by concurrent repression of major cholesterol efflux mediators (for example, ATP-binding cassette A1 (ABCA1), ATP-binding cassette G1 (ABCG1) and apolipoprotein [Apo]-E), leading to foam cell formation (9) . AEBP1 was also shown to promote macrophage inflammatory responsiveness by inducing nuclear factor (NF)-κB activity via IκBα-negative regulation through protein-protein interaction (10) . These experimental findings strongly suggest that AEBP1 may exert potent atherogenic effects in vivo. We hypothesize that AEBP1 overexpression promotes lesion formation, while AEBP1 ablation attenuates lesion formation in ApoE -/-and
low-density lipoprotein receptor (LDLR )
-/-murine models of atherosclerosis.
In this study, ablation of AEBP1 (12) tion, mice were placed on an atherogenic diet for 16 wks and then sacrificed to isolate BM cells and spleens for real-time PCR.
MATERIALS AND METHODS

Animal Experiments
Mice were deeply anesthetized with isoflurane, and blood was obtained by intracardiac puncture. Plasma cholesterol and triglyceride levels were determined by enzymatic assays (Roche Diagnostics, Laval, QC, Canada, and Sigma, St. Louis, MO, USA). The aortas and hearts were isolated for en face and aortic root atherosclerotic lesion analysis.
All animal experiments were performed according to procedures approved by the Institutional Animal Care Committee (Carleton Animal Care Facility, Dalhousie University, Halifax, NS, Canada). Age-matched mice were kept on a 12-h light cycle.
Atherosclerotic Lesion Analysis
For en face analysis, aorta isolation and detection of atherosclerotic lesions using sudan IV were performed as previously described (14) , and images were captured with a PixeLINK PL-A686C camera attached to a Leica MZ6 dissecting microscope. Aortic cryosection analysis of atherosclerotic lesions in the proximal aortic root was performed as previously described (15) , and photomicroscopy was performed on a Nikon Eclipse E600 microscope attached to a Nikon Coolpix 990 camera. In all cases, the percentage of stained lesion size was determined using ImageJ analysis software.
Immunohistochemistry for Aortic Cryosection
The hearts were harvested from AEBP1
mice fed an atherogenic diet for 13 wks and were fixed in 10% buffered formalin overnight. The next day, the hearts were put in 0.02% sodium azide in phosphatebuffered saline. Consecutive 5-μm cryosections of the heart from the aortic sinus to the beginning of the aortic arch were subjected to immunohistochemistry using rat anti-mouse F4/80 (Abcam, San Francisco, CA, USA) for macrophage detection, rat anti-mouse CD106 for vascular cell adhesion molecule 1 (VCAM-1) detection (BD Pharmingen, San Diego, CA, USA), rat anti-mouse CD3 for T-cell detection (BD Pharmingen) and normal rat IgG as a negative control.
Macrophage Isolation
Macrophages were isolated from the spleen using EasySep specific antibodies and tiny fluorescence-activated cell sorter (FACS)-compatible magnetic nanoparticles in a column-free magnetic system (StemCell Technologies). Purity (~98%) was confirmed by flow cytometry.
RNA and Protein Analysis
Total RNA was isolated from the spleen and BM cells using TRIZOL (Invitrogen, Burlington, ON, Canada) and was then reverse-transcribed into cDNA using an iScript cDNA synthesis kit (BioRad, Mississauga, ON, Canada). PCR was performed using a CFX96 optical reaction module (Bio-Rad). Protein extraction and immunoblotting were performed as previously described (13) .
Statistical Analysis
Group means were compared with a Student t test. A probability value of ≤0.05 was considered statistically significant. All data are reported as mean ± standard error of the mean (SEM) as indicated.
All supplementary materials are available online at www.molmed.org.
RESULTS
AEBP1
TG Mice Exhibit Signs of
Atherosclerotic Lesion Formation in a Gender-Influenced Manner
The fact that AEBP1 overexpression causes cholesterol homeostasis imbalance in macrophages (9,11) prompted us to examine the serum lipid profile in AEBP1 TG mice that overexpress AEBP1 in macrophages (9 Table 1 ) and of a larger mean area (Table 2) . Figure 3C ), despite the significant (P = 0.004) reduction in feed efficiency of those males ( Figure 3D ). Although AEBP1
AEBP1 Ablation Reduces
-/-/LDLR -/-females display significantly (P = 0.006) increased energy intake (see Figure 3C ), their body weight values were slightly, but not significantly, reduced (see Figure 3D ). Taken together, these results demonstrate that AEBP1 ablation not only attenuates atherosclerotic lesion development in vivo, but also possibly influences lipid and energy metabolism.
BM-Derived AEBP1 Is Critical in Atherogenesis
We have previously shown that AEBP1 plays a key functional role in modulating in vivo adiposity and energy metabolism To further confirm that macrophage AEBP1 plays a critical role in the development of atherosclerosis, we generated more BM-chimeric mice, using the ApoE /TG-BM mice in a gender-influenced manner (4.7-fold, P = 0.0001, versus 3.0-fold, P = 0.0001) (Figure 5C) . Notably, although transplantation of AEBP1 TG BM cells into ApoE -/-mice led to a significant elevation of plasma cholesterol and triglyceride levels in male and female recipients ( Figure 5D ), this difference did not reach statistical significance, as in the case of AEBP1 TG males (Figure 1 ).
BM-Derived AEBP1 Promotes Atherosclerosis by Downregulating Cholesterol Efflux Mediators PPARγ1 and LXRα and Provoking Macrophage Inflammatory Responsiveness
We have previously shown that AEBP1 promotes foam cell formation by downregulating PPARγ1, LXRα and their downstream target genes (9, 11) . To examine whether AEBP1 modulates PPARγ1 and LXRα expression in macrophages of the chimeric mice, macrophage protein extracts were subjected to immunoblotting ( Figure 6A ). Quantification analysis revealed more than a 3.0-fold (P = 0.0001) and 1.8-fold (P = 0.0001) decrease in protein levels of PPARγ1 and LXRα, respectively, in ApoE -/-/TG-BM macro phages ( Figure 6B) . Similarly, real-time PCR analysis revealed that transplantation of Figure 6C) .
Proinflammatory cytokines have been implicated as key mediators in atherogenesis. We have previously shown that AEBP1 overexpression in macrophages is accompanied by a significant increase in the production of major proinflammatory mediators including IL-6 and tumor necrosis factor (TNF)-α (9). Here, the expression of IL-6 and TNF-α was examined in the macrophages of BM-chimeric ApoE -/-mice.
As shown in Figure 6C , IL-6 and TNF-α levels were significantly (P = 0.0001) elevated (1. 
DISCUSSION
It has been well established that mice are particularly resistant to the formation of atherosclerotic lesions (19, 20) . Even when fed a HCD (100 times their normal daily intake), mice do not show signs of atherogenesis (21) . Nevertheless, two widely recognized genetically altered mouse models exist that spontaneously develop lesions; ApoE -/-mice fed a standard diet (22, 23) and LDLR -/-mice fed a HCD (24) . In this study, we identify Table 1 ) and of a larger mean area (see Table 2 ). Despite the low number of samples used, these data are consistent with other studies suggesting that HFD-fed female mice are more susceptible to lesion formation compared with HFD-fed male mice (27) (28) (29) (30) . Several explanations were provided to account for gender-specific differences with regard to athero-susceptibility (27) (28) (29) (30) (31) (32) . The only satisfactory explanation for the gender-specific, athero-susceptibility differences in AEBP1 TG mice is that AEBP1 TG females, but not males, have significantly elevated cholesterol and triglyceride serum levels compared with their AEBP1
NT counterparts ( Figure 1A ). This gender-specific effect is most unlikely due to alteration of sex hormones in the AEBP1 TG females, in which assessment of serum estrogen levels did not reveal any significant difference between AEBP1 TG females and
Many studies have demonstrated that promotion or inhibition of atherogenesis is not always preceded or accompanied by changes in the plasma lipoprotein profile (31, 33, 34) . Here, it is important to emphasize that atherogenesis can be initiated and advanced despite normal plasma lipoprotein profile. Interestingly, AEBP1 TG males, which have plasma cholesterol and triglyceride levels that are statistically comparable to their AEBP1 NT male counterparts (see Figure 1A) , clearly develop atherosclerotic lesions (see Table 1 ). Figure 1A) . Figure 2 ). It has been previously shown that infiltration of T cells into the atherosclerotic lesions is a crucial event in the early phase of atherogenesis, and as the disease progresses, macrophage recruitment and activation intensify and macrophages become the predominant cell type during the late phase of atherosclerosis (35) (36) (37) (38) . It is interesting to speculate that AEBP1 is not only important in controlling macrophage infiltration during the late phase of atherogenesis, but it may also be critically involved in the early phase of the disease.
To enable investigation of a potential direct and specific role of AEBP1 in atherogenesis, we generated AEBP1 TG / LDLR -/-hybrid mice. However, atherosclerotic lesion analysis in the hybrid mice did not yield any meaningful results, possibly because of the mixedstrain effect on atherosclerotic lesion development in the hybrid mice. To avoid the strain effect, we generated AEBP1 -/-/ LDLR -/-double-knockout mice on the same C57BL/6 background. These double-knockout mice exhibited significant resistance to atherosclerotic lesion development compared with the control AEBP1 +/+ /LDLR -/-mice (see Figure 2 ).
However, this may be due to a compound effect of global disruption of AEBP1 in the double-knockout mice (see Figure 3 ). To definitively evaluate the functional role of AEBP1 signaling in atherogenesis and to investigate a direct role of macrophage AEBP1 in the development of atherosclerosis, we also generated chimeric mice by BM transplantation. Experimental evidence suggests that while transplantation of AEBP1 -/-BM cells into LDLR -/-recipients attenuates lesion formation (see Figure 4) , transplantation of AEBP1 TG BM cells into ApoE -/-re- cipients enhances lesion formation (see Figure 5 ) by downregulating cholesterol efflux mediators PPARγ1 and LXRα and provoking macrophage inflammatory responsiveness (see Figure 6 ). Our findings strongly suggest that macrophage AEBP1 plays a critical role in the development of atherosclerosis. The potential pro-atherogenic properties of AEBP1 may be a byproduct of a vital interplay of its ability to antagonize PPARγ1 and LXRα cholesterol efflux functions in macrophages and its ability to promote inflammation via enhanced NF-κB transcriptional activity (39, 40) . We anticipate that AEBP1 may serve as a molecular candidate toward the development of therapeutic strategies to ameliorate or attenuate atherogenesis.
